keyword
MENU ▼
Read by QxMD icon Read
search

triple breast cancer

keyword
https://www.readbyqxmd.com/read/28726519/cancer-stem-cells-cd133-inhibition-and-cytotoxicity-of-certain-3-phenylthiazolo-3-2-a-benzimidazoles-design-direct-synthesis-crystal-study-and-in-vitro-biological-evaluation
#1
Ghada H Al-Ansary, Wagdy M Eldehna, Hazem A Ghabbour, Sara T A Al-Rashood, Khalid A Al-Rashood, Radwa A Eladwy, Abdullah Al-Dhfyan, Maha M Kabil, Hatem A Abdel-Aziz
Cancer stem cells (CSCs) have been objects of intensive study since their identification in 1994. Adopting a structural rigidification approach, a novel series of 3-phenylthiazolo[3,2-a]benzimidazoles 4a-d was designed and synthesised, in an attempt to develop potent anticancer agent that can target the bulk of tumour cells and CSCs. The anti-proliferative activity of the synthesised compounds was evaluated against two cell lines, namely; colon cancer HT-29 and triple negative breast cancer MDA-MB-468 cell lines...
December 2017: Journal of Enzyme Inhibition and Medicinal Chemistry
https://www.readbyqxmd.com/read/28726194/association-between-the-prevalence-of-somatic-mutations-in-pik3ca-gene-in-tumors-and-clinical-and-morphological-characteristics-of-breast-cancer-patients
#2
M L Filipenko, N A Os'kina, I A Oskorbin, O V Mishukova, L K Ovchinnikova, E S Gershtein, N E Kushlinskii
The presence of activating somatic mutations in codons 542 and 545 of exon 9 (p.E542K c.1624G>A and p.E545K c.1633G>A) and in codon 1047 of exon 20 (p.H1047R c.3140A>G and p.H1047L c.3140A>T) of PIK3CA gene encoding catalytic p110α-subunit of phosphatidylinositol-3-kinase was studied in tumors of 473 breast cancer patients by multiplex allele-specific real-time PCR. Fifty-eight (12.3%) different mutations were found. An increase in the frequency of PIK3CA gene mutations with disease progression (from 2...
July 18, 2017: Bulletin of Experimental Biology and Medicine
https://www.readbyqxmd.com/read/28725277/sabcs-2016-systemic-therapy-for-metastatic-breast-cancer
#3
REVIEW
Simon Peter Gampenrieder, Gabriel Rinnerthaler, Richard Greil
At the 2016 San Antonio Breast Cancer Symposium, several interesting phase II and phase III studies investigating systemic therapies for metastatic breast cancer were presented. The PrEGOC 0102 trial demonstrated that the combination of fulvestrant plus everolimus is safe and effective and could be an alternative to exemestane plus everolimus for selected patients with hormone-receptor positive, HER2-negative disease. The pan-PI3K inhibitor buparlisib showed some activity in combination with fulvestrant after failure of everolimus in the BELLE-3 trial...
2017: Memo
https://www.readbyqxmd.com/read/28724667/germline-mutations-in-cancer-susceptibility-genes-in-a-large-series-of-unselected-breast-cancer-patients
#4
Jie Sun, Hua Meng, Lu Yao, Meng Lv, Jian Bai, Jianguang Zhang, Lientu Wang, Tao Ouyang, Jinfeng Li, Tianfeng Wang, Zhaoqing Fan, Tie Fan, Benyao Lin, Yuntao Xie
PURPOSE: The prevalence of mutations in cancer susceptibility genes such as BRCA1 and BRCA2 and other cancer susceptibility genes and their clinical relevance are largely unknown among a large series of unselected breast cancer patients in Chinese population. <p> </p> <p>METHODS: A total of 8085 consecutive unselected Chinese breast cancer patients were enrolled. Germline mutations in 46 cancer susceptibility genes were detected using a 62-gene panel.</p> <p> </p> <p>RESULTS: Pathogenic mutations were identified in 9...
July 19, 2017: Clinical Cancer Research: An Official Journal of the American Association for Cancer Research
https://www.readbyqxmd.com/read/28724549/identification-of-new-tumor-suppressor-genes-in-triple-negative-breast-cancer
#5
Roberto Rangel, Liliana Guzman-Rojas, Takahiro Kodama, Michiko Kodama, Justin Y Newberg, Neal G Copeland, Nancy A Jenkins
Although genomic sequencing has provided a better understating of the genetic landmarks in triple-negative breast cancer (TNBC), functional validation of candidate cancer genes (CCG) remains unsolved. In this study, we used a transposon mutagenesis strategy based on a two-step Sleeping Beauty (SB) forward genetic screen to identify and validate new tumor suppressors (TS) in this disease. We generated 120 siRNAs targeting 40 SB-identified candidate breast cancer TS genes and used them to downregulate expression of these genes in four human TNBC cell lines...
July 19, 2017: Cancer Research
https://www.readbyqxmd.com/read/28724364/tamoxifen-reverses-epithelial-mesenchymal-transition-by-demethylating-mir-200c-in-triple-negative-breast-cancer-cells
#6
Qian Wang, Yu Cheng, Yan Wang, Yibo Fan, Ce Li, Ye Zhang, Yiding Wang, Qian Dong, Yanju Ma, Yue-E Teng, Xiujuan Qu, Yunpeng Liu
BACKGROUND: Although the efficacy of tamoxifen (TAM) for breast cancer has been attributed to inducing cell cycle arrest and apoptosis by inhibiting estrogen receptor (ER) signaling, recent evidence indicates that TAM also possesses ER-independent antitumor activity through an unclear mechanism. The present study investigated the anti-tumor mechanism of TAM on mesenchymal triple-negative breast cancer (TNBC). METHODS: The inhibitory effect of TAM on tumor migration and metastasis was analyzed by transwell chamber in vitro and by murine xenograft model in vivo...
July 19, 2017: BMC Cancer
https://www.readbyqxmd.com/read/28723722/complementary-and-alternative-medicine-use-and-symptom-burden-in-women-undergoing-chemotherapy-for-breast-cancer-in-malaysia
#7
Ping Lei Chui, Khatijah Lim Abdullah, Li Ping Wong, Nur Aishah Taib
BACKGROUND: Complementary and alternative medicine (CAM) is commonly used for cancer- and chemotherapy-related symptoms. Nurses are likely to encounter many CAM users in their practice. OBJECTIVE: The aims of this study were to assess CAM use and examine the symptom burden of CAM and non-CAM users among patients with breast cancer who are undergoing chemotherapy. METHODS: A CAM use questionnaire and the Side-Effect Burden Scale were administered to 546 patients...
July 14, 2017: Cancer Nursing
https://www.readbyqxmd.com/read/28723663/a-network-meta-analysis-on-the-efficacy-of-targeted-agents-in-combination-with-chemotherapy-for-treatment-of-advanced-metastatic-triple-negative-breast-cancer
#8
Long Ge, Yan Tang, Qiu-Ning Zhang, Jin-Hui Tian, Xiao-Hu Wang, Dawid Pieper, Bei Pan, Lun Li, Juan Ling, Zhi-Tong Bing, Ke-Hu Yang
OBJECTIVE: Our network meta-analysis aimed to determine the assistant efficacy of targeted therapy in combined with chemotherapy for advanced/metastatic triple-negative breast cancer (TNBC). RESULTS: A total of 15 randomized controlled trials (RCTs), involving 2,410 patients, met our inclusion criteria. Eight targeted agents involving 11 treatment arms were included. The methodological quality of included RCTs was acceptable. The results of direct comparisons showed that progression-free survival (PFS) was significantly longer with bevacizumab+chemotherapy when compared to chemotherapy alone (hazard ratio [HR] = 0...
July 8, 2017: Oncotarget
https://www.readbyqxmd.com/read/28721678/pim1-a-promising-target-in-patients-with-triple-negative-breast-cancer
#9
REVIEW
Wen Zhao, RuiYue Qiu, Pan Li, Jin Yang
Triple-negative breast cancers (TNBCs) have poor prognosis, and chemotherapy remains the mainstay of therapy because of lack of discovered possible target. MYC were found overexpressed in TNBCs compared with other subtypes and especially in those resistant to chemotherapy, but the inhibition has been challenging to achieve. Recently, the cooperation of PIM1 and MYC was identified involved in cell proliferation, migration and apoptosis of TNBCs, which has been reported in hematological malignancy and prostatic cancer...
August 2017: Medical Oncology
https://www.readbyqxmd.com/read/28721639/erratum-to-frequency-of-germline-dna-genetic-findings-in-an-unselected-prospective-cohort-of-triple-negative-breast-cancer-patients-participating-in-a-platinum-based-neoadjuvant-chemotherapy-trial
#10
Milagros González-Rivera, Miriam Lobo, Sara López-Tarruella, Yolanda Jerez, María Del Monte-Millán, Tatiana Massarrah, Rocío Ramos-Medina, Inmaculada Ocaña, Antoni Picornell, Sonia Santillán Garzón, Lucía Pérez-Carbornero, José A García-Saenz, Henry Gómez, Fernando Moreno, Iván Márquez-Rodas, Hugo Fuentes, Miguel Martin
No abstract text is available yet for this article.
July 18, 2017: Breast Cancer Research and Treatment
https://www.readbyqxmd.com/read/28720897/a-predictive-mathematical-modeling-approach-for-the-study-of-doxorubicin-treatment-in-triple-negative-breast-cancer
#11
Matthew T McKenna, Jared A Weis, Stephanie L Barnes, Darren R Tyson, Michael I Miga, Vito Quaranta, Thomas E Yankeelov
Doxorubicin forms the basis of chemotherapy regimens for several malignancies, including triple negative breast cancer (TNBC). Here, we present a coupled experimental/modeling approach to establish an in vitro pharmacokinetic/pharmacodynamic model to describe how the concentration and duration of doxorubicin therapy shape subsequent cell population dynamics. This work features a series of longitudinal fluorescence microscopy experiments that characterize (1) doxorubicin uptake dynamics in a panel of TNBC cell lines, and (2) cell population response to doxorubicin over 30 days...
July 18, 2017: Scientific Reports
https://www.readbyqxmd.com/read/28720841/novel-immunohistochemistry-based-signatures-to-predict-metastatic-site-of-triple-negative-breast-cancers
#12
Sergey Klimov, Padmashree Cg Rida, Mohammed A Aleskandarany, Andrew R Green, Ian O Ellis, Emiel Am Janssen, Emad A Rakha, Ritu Aneja
BACKGROUND: Although distant metastasis (DM) in breast cancer (BC) is the most lethal form of recurrence and the most common underlying cause of cancer related deaths, the outcome following the development of DM is related to the site of metastasis. Triple negative BC (TNBC) is an aggressive form of BC characterised by early recurrences and high mortality. Athough multiple variables can be used to predict the risk of metastasis, few markers can predict the specific site of metastasis...
July 18, 2017: British Journal of Cancer
https://www.readbyqxmd.com/read/28720062/hes1-overexpression-promotes-cell-proliferation-and-invasion-in-breast-cancer-and-predicts-poor-survival
#13
Xiaoying Li, Yu Cao, Mu Li, Feng Jin
HES1 is a transcriptional repressor involved in cell differentiation and proliferation, but the expression pattern and biological roles of HES1 in breast cancer have not been examined. In this study, we examined HES1 expression in breast cancer tissues using immunohistochemistry and western blot analyses and investigated HES1 function using 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide and Matrigel invasion assays. Significant relationships were observed between HES1 upregulation and advanced tumour-node-metastasis stage (p = 0...
July 2017: Tumour Biology: the Journal of the International Society for Oncodevelopmental Biology and Medicine
https://www.readbyqxmd.com/read/28718331/entinostat-for-the-treatment-of-breast-cancer
#14
Dario Trapani, Angela Esposito, Carmen Criscitiello, Luca Mazzarella, Marzia Locatelli, Ida Minchella, Saverio Minucci, Giuseppe Curigliano
Breast cancer accounts for 29% of malignant tumors. It is an heterogenous disease covering a spectrum of different molecular subtypes. Epigenetic aberrations may affect gene expression through DNA and histone proteins modifications thus promoting tumor progression and resistance to anti- tumor treatment. Area covered: This article explores the potential role of entinostat in the treatment of breast cancer. The clinical trials evaluating entinostat are discussed, highlighting preclinical data and early-phase clinical studies results...
July 18, 2017: Expert Opinion on Investigational Drugs
https://www.readbyqxmd.com/read/28717943/a-pyrrole-based-natural-small-molecule-mitigates-hsp90-expression-in-mda-mb-231-cells-and-inhibits-tumor-angiogenesis-in-mice-by-inactivating-hsf-1
#15
K C Rashmi, H S Atreya, M Harsha Raj, Bharathi P Salimath, H S Aparna
Heat shock proteins (HSPs), molecular chaperones, are crucial for the cancer cells to facilitate proper functioning of various oncoproteins involved in cell survival, proliferation, migration, and tumor angiogenesis. Tumor cells are said to be "addicted" to HSPs. HSPs are overexpressed in many cancers due to upregulation of transcription factor Heat-shock factor 1 (HSF-1), the multifaceted master regulator of heat shock response. Therefore, pharmacological targeting of HSPs via HSF-1 is an effective strategy to treat malignant cancers like triple negative breast cancer...
July 17, 2017: Cell Stress & Chaperones
https://www.readbyqxmd.com/read/28717757/immunohistochemistry-heterogeneity-in-reported-breast-cancer-demographics-from-india-triple-negative-breast-cancer-rates-could-be-lower-than-suggested-in-pooled-meta-analysis
#16
Sanjoy Chatterjee, Indu Arun, Sanjit Agrawal, Moses Arunsingh, Indranil Mallick, Rosina Ahmed
No abstract text is available yet for this article.
April 2017: Journal of Global Oncology
https://www.readbyqxmd.com/read/28717728/prevalence-of-triple-negative-breast-cancer-in-india-systematic-review-and-meta-analysis
#17
REVIEW
Gurprataap S Sandhu, Sebhat Erqou, Heidi Patterson, Aju Mathew
PURPOSE: There is considerable variation in prevalence rates of triple-negative breast cancer (TNBC) reported by various studies from India. We performed a systematic review and literature-based meta-analysis of these studies. METHODS: We searched databases of Medline, Scopus, EMBASE, and Web of Science for studies that reported on the prevalence of TNBC in India that were published between January 1, 1999, and December 31, 2015. We extracted relevant information from each study by using a standardized form...
December 2016: Journal of Global Oncology
https://www.readbyqxmd.com/read/28717716/breast-cancer-and-african-ancestry-lessons-learned-at-the-10-year-anniversary-of-the-ghana-michigan-research-partnership-and-international-breast-registry
#18
Evelyn Jiagge, Joseph Kwaku Oppong, Jessica Bensenhaver, Francis Aitpillah, Kofi Gyan, Ishmael Kyei, Ernest Osei-Bonsu, Ernest Adjei, Michael Ohene-Yeboah, Kathy Toy, Karen Eubanks Jackson, Marian Akpaloo, Dorcas Acheampong, Beatrice Antwi, Faustina Obeng Agyeman, Zainab Alhassan, Linda Ahenkorah Fondjo, Osei Owusu-Afriyie, Robert Newman Brewer, Amma Gyamfuah, Barbara Salem, Timothy Johnson, Max Wicha, Sofia Merajver, Celina Kleer, Judy Pang, Emmanuel Amankwaa-Frempong, Azadeh Stark, Francis Abantanga, Lisa Newman, Baffour Awuah
Women with African ancestry in western, sub-Saharan Africa and in the United States represent a population subset facing an increased risk of being diagnosed with biologically aggressive phenotypes of breast cancer that are negative for the estrogen receptor, the progesterone receptor, and the HER2/neu marker. These tumors are commonly referred to as triple-negative breast cancer. Disparities in breast cancer incidence and outcome related to racial or ethnic identity motivated the establishment of the International Breast Registry, on the basis of partnerships between the Komfo Anokye Teaching Hospital in Kumasi, Ghana, the University of Michigan Comprehensive Cancer Center in Ann Arbor, Michigan, and the Henry Ford Health System in Detroit, Michigan...
October 2016: Journal of Global Oncology
https://www.readbyqxmd.com/read/28717401/novel-therapeutic-strategies-in-the-treatment-of-triple-negative-breast-cancer
#19
REVIEW
Karima Oualla, Heba M El-Zawahry, Banu Arun, James M Reuben, Wendy A Woodward, Heba Gamal El-Din, Bora Lim, Nawfel Mellas, Naoto T Ueno, Tamer M Fouad
Triple-negative breast cancer (TNBC) is a heterogeneous subtype of breast cancer that is defined by negative estrogen receptor (ER), progesterone receptor (PR) and human epidermal growth factor receptor 2 (HER2) status. Treating patients with TNBC remains clinically challenging, as patients are not candidates for endocrine or HER2-directed therapy. As a result, chemotherapy with traditional agents such as anthracyclines and taxanes remains the only available option with moderate success. Recent discoveries have revealed that TNBC is a heterogeneous disease at the clinical, histological and molecular levels...
July 2017: Therapeutic Advances in Medical Oncology
https://www.readbyqxmd.com/read/28715872/a-novel-compound-lingh2-10-inhibits-the-growth-of-triple-negative-breast-cancer-cells-in-vitro-and-in-vivo-as-a-selective-inverse-agonist-of-estrogen-related-receptor-%C3%AE
#20
Yang Ning, Haifei Chen, Yongli Du, Hao Ling, Liudi Zhang, Lu Chen, Huijie Qi, Xiaojin Shi, Qunyi Li
Unlike other breast cancer subtypes, targeted therapies for triple negative breast cancer (TNBC) have yet to progress past clinical trial stage to approval. Accumulating evidences demonstrated that expression of estrogen-related receptor alpha (ERRα) indicated worse prognosis and correlated with poor outcome in breast cancers including TNBC. Therefore, ERRα modulators/regulators may be potential in the therapeutic treatment of breast cancers. In the current study, we presented a novel compound LingH2-10 that bound to ERRα, as identified using a time-resolved fluorescence resonance energy transfer assay (TR-FRET) with the IC50 value of 0...
July 13, 2017: Biomedicine & Pharmacotherapy, Biomédecine & Pharmacothérapie
keyword
keyword
118754
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"